Cargando…
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
INTRODUCTION: The SARS-CoV-2 pandemic necessitated better understanding of the impact of disease-modifying therapies on COVID-19 outcomes and vaccination. We report characteristics of COVID-19 cases and vaccination status in ofatumumab-treated relapsing multiple sclerosis (RMS) patients. METHODS: CO...
Autores principales: | Cross, Anne H., Delgado, Silvia, Habek, Mario, Davydovskaya, Maria, Ward, Brian J., Cree, Bruce A. C., Totolyan, Natalia, Pingili, Ratnakar, Mancione, Linda, Hu, Xixi, Sullivan, Roseanne, Su, Wendy, Zielman, Ronald, Gupta, Ayan Das, Montalban, Xavier, Winthrop, Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918079/ https://www.ncbi.nlm.nih.gov/pubmed/35284994 http://dx.doi.org/10.1007/s40120-022-00341-z |
Ejemplares similares
-
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022) -
Safety experience with continued exposure to ofatumumab in patients
with relapsing forms of multiple sclerosis for up to 3.5 years
por: Hauser, Stephen L, et al.
Publicado: (2022) -
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
por: Yu, Huixin, et al.
Publicado: (2022) -
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
por: Kramer, John, et al.
Publicado: (2023) -
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
por: Hauser, Stephen L, et al.
Publicado: (2023)